Navigation Links
VIVUS to Present at Lazard Capital Markets Healthcare Conference
Date:11/11/2009

MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Lazard Capital Markets 6th Annual Healthcare Conference.

The VIVUS presentation will take place at The St. Regis in New York, NY on Wednesday, November 18, 2009 at 1:45 p.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.                 Investor Relations: The Trout Group
    Timothy E. Morris                               Brian Korb
    Chief Financial Officer                         646-378-2923
    650-934-5200
                                Media Relations:    Pure Communications, Inc.
                                                    Dan Budwick
                                                    973-271-6085

'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Surgical Theater, LLC announced today the ... Advisory Board. New members include Ori J. ... Development and New Technologies for Given Imaging Ltd., ... Vice President and General Manager of Philips Healthcare,s ... simulation technology to brain surgery and has developed ...
(Date:7/28/2014)...  VigeneTech, Inc, in collaboration with BioLegend, Inc., ... Software, an OEM software solution for analysis of ... offers varieties of bead-based multi-analyte immunoassay products for ... VigeneTech,s data analysis software, FCS data files can ... LEGENDplex™ software is a robust ...
(Date:7/28/2014)... , July 28, 2014  Array BioPharma Inc. ... for the fourth quarter and full year ... call to discuss those results on Tuesday, ... Officer and Michael Carruthers , Chief ... InformationDate:Tuesday, August 12, 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) ...
Breaking Medicine Technology:Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 2Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 5VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2
... THOUSAND OAKS, Calif., Nov. 5, 2011 Amgen ... the first three years of the open-label extension study of ... of Prolia® (denosumab) treatment in postmenopausal women with osteoporosis was ... consistent reduction in markers of bone turnover. These results will ...
... Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) ... analysis of PILLAR, a phase 2b study of the ... in treatment-naive patients with chronic genotype 1 HCV, as ... Annual Meeting of the American Association for the Study ...
Cached Medicine Technology:Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 2Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 3Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 4Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 5Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 6Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 7Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 8Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 9Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD 2Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD 3Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD 4
(Date:7/29/2014)... July 29, 2014 Current Back2Basics long-term ... pain medication post foot surgery during his first six months ... foot surgery – twice on one foot, once on the ... “I broke my foot a year ago and was prescribed ... to Jon by a friend from home who’d recently completed ...
(Date:7/29/2014)... Consilium Staffing, Your Partner in Locum Tenens, ... point of 2014, with strong indications the Irving, Texas-based firm ... this year. , “This is a great time to be ... Staffing. , “We are proud of what we have ... are even more excited about how things are shaping up ...
(Date:7/29/2014)... July 29, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
(Date:7/29/2014)... latest blog post at http://www.perwickstrom.com , entrepreneur, author, speaker ... ways to light the “fire” in employees. , “Employers are ... some it’s a losing battle,” commented Per Wickstrom . ... employees get to the next level; which not only helps ... Per Wickstrom, 6 ways to light the “fire” in employees ...
(Date:7/29/2014)... Angeles, CA (PRWEB) July 29, 2014 ... of 3.1 out of 5. This score reflects a ... result of the large number of suppliers, the product's ... tank market, says IBISWorld analyst Jordan Weinstein. IBISWorld estimates ... buyers with a substantial number of supplier options. However, ...
Breaking Medicine News(10 mins):Health News:Back2Basics Sober Living Resident Overcomes Obstacle in Early Sobriety 2Health News:Consilium Staffing Experiences Significant Revenue Growth 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Per Wickstrom’s Latest Blog Post Lists 6 Ways to Light the “Fire” in Employees 2Health News:Septic Tanks Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Septic Tanks Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Septic Tanks Procurement Category Market Research Report Now Available from IBISWorld 4
... COLUMBIA, Mo. Nursing is among construction and law ... on-the-job injuries, according to the U.S. Department of Labor. ... many of the injuries. Those injuries often can be ... nursing students at the University of Missouri have a ...
... a hormone disorder that causes a diverse array of ... wasting, and ultimately death. It is caused by a ... the secretion of excess amounts of adrenocorticotropic hormone (ACTH). ... tumors commonly recur, meaning that new treatment options are ...
... (HealthDay News) -- Among older married Americans, an active sex ... with life in general, according to a new study. ... of 238 married people 65 and older who took part ... predicted both overall and marital happiness, and this association remained ...
... use to rate nursing home quality does not provide ... account the degree of cognitive impairment of their patient ... according to a new study. Focusing on statistics ... and the Regenstrief Institute report on the inadequacy of ...
... A patient,s viewpoint of the severity of irritable bowel ... physical symptoms of IBS but broader psychological problems, according ... Hepatology , the official journal of the American Gastroenterological ... in a cost-effective manner within tight time constraints and ...
... 20 (HealthDay News) -- Holiday foods and feasts can ... gastroesophageal reflux disease (GERD), but there are things they ... GERD occurs when a faulty valve between the ... into the esophagus. Symptoms of GERD include heartburn, acid ...
Cached Medicine News:Health News:New safe practices room provides prevention training space for nursing students 2Health News:Regular Sex May Be Key to Happy Marriage for Seniors 2Health News:Nursing home quality scorecards don't tell the whole score 2Health News:Psychological factors affect IBS patients' interpretation of symptom severity 2Health News:Holiday Foods May Trigger GERD Symptoms 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: